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Bevacizumab, a monoclonal antibody against vascular endothelial growth 
factor (VEGF) (Avastin®, Genentech, South San Francisco, CA and Roche, Basel, 
Switzerland) was approved in 2009 by the Food and Drug Administration (FDA) for 
the treatment of recurrent glioblastoma. The basis for this accelerated approval were 
uncontrolled phase II trials with a total of 215 patients; a single arm phase II trial of 
bevacizumab with irinotecan added at progression and a randomized phase II trial of 
the same regimen or upfront treatment with the combination of bevacizumab and 
irinotecan.2 Even prior to FDA approval bevacizumab was widely used in this 
indication in the US, and variably in European countries and is currently given on an 
off-label protocol for newly diagnosed high-grade glioma patients. The marketing 
application to European Medicines Agency (EMEA) is still under review. 
 It is remarkable that over the three years since the first report on efficacy of 
bevacizumab in recurrent glioblastoma only a few hundred recurrent glioblastoma 
patients were accrued into reported prospective clinical trials, while already 
thousands of patients have been treated off-label. Despite the rapid FDA approval 
numerous questions with regard to dosing, timing, and efficacy remain. Opportunities 
to adequately test this promising agent were missed or avoided. This has already led 
to considerable national differences with respect to access and reimbursement of 
bevacizumab for glioma patients. 
 
Based on the reported and our own clinical experience bevacizumab is without doubt 
a useful drug in recurrent glioma. However, the pivotal uncontrolled trials that 
evaluated bevacizumab and irinotecan versus bevacizumab alone (and the addition 
of irinotecan at progression) leaves many questions unanswered.  
First, was the right endpoint used? The primary endpoint was the rate of patients 
being alive and free of progression at 6 months (PFS6), a surrogate endpoint that 
had been considered valuable for cytotoxic agents, but is inappropriate when 
studying antiangiogenic agents that will modify vascular permeability and thus the 
imaging response assessment based on contrast enhancement.3,4 VEGF was initially 
also referred to as vascular permeability factor (VPF)5 and it is well recognized that 
VEGF is a major mediator of blood brain barrier disturbance. Inhibiting VEGF 
signalling decreases tumor enhancement even without an intrinsic anti-tumor effect. 
Indeed, clinical progression has been observed in the absence of evident tumor 
progression on T1-gadolinium-enhanced magnetic resonance imaging (MRI) with T2-
weighted sequences showing tumor extension without disruption of the blood-brain 
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barrier.6 The substantial differences in response rates when independently assessed 
by the investigators (39% and 46% for bevacizumab and bevacizumab with 
irinotecan, respectively), by a sponsor-mandated central radiological review (28% 
and 38%)1 and finally by the FDA (20% and 26%)7 illustrate the difficulties and 
limitations of objective response as the primary endpoint for outcome to treatment 
with anti-angiogenic agents. Of note, an international panel is currently revisiting the 
response criteria for brain tumors8, and has judged response rate for anti-VEGF 
signaling treatments inappropriate.3 
Secondly, does treatment with bevacizumab increase survival? The reported survival 
times of 8-9 months correspond to what had been reported as median survival after 
progression for patients treated with radiotherapy alone, or radiotherapy and 
concomitant temozolomide9 before the availability of bevacizumab and needs to be 
compared to 6-7 months in many bluntly negative trials on recurrent glioblastoma.10 
The disappointing disparity between the high response rates reported for 
bevacizumab in recurrent glioblastoma and the at best modest survival benefit may 
be partly explained a limited effect on the tumor mass itself.11 The obvious question 
is whether the effects of bevacizumab by and large resemble that of dexamethasone 
and should therefore be named ‘pseudo-response’.3 The duration of a response and 
ultimately overall survival are to be considered more accurate indicators of the 
therapeutic activity of a compound. The data reported in this Journal1 remains 
immature, with a minimum follow-up of only 6 months and just half of the patients 
having died at the time of analysis in September 2007, two years before publication 
(!). No update has been made available yet. 
Thirdly, do we know the optimal bevacizumab dose? Stark-Vance’s initial experience 
on of high response rates in recurrent glioma with bevacizumab used a dose of 5 
mg/kg every 2 weeks12, nevertheless the dose of bevacizumab in subsequent trials 
was doubled without further investigations or justification.One cannot rule out that the 
higher dose of bevacizumab actually increases toxicity and complication rate, this not 
even considering the economical impact.  
Fourthly, should bevacizumab be given as a single agent or in combination ? In most 
indications anti-VEGF agents are to be combined with classical cytotoxic drugs. 
Based on overall survival, the current trial shows little added benefit of irinotecan 
when looking at overall survival, and a marginal improvement in response rate. Yet, 
irinotecan adds to the toxicity of the regimen.1 Anti-VEGF signaling drugs may 
increase the penetration of co-medication into tumors by reducing the intratumoral 
pressure and through normalization of abnormal and non-functional capillary 
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networks, or is drug penetration decreased by restoring the blood-brain barrier ? 12 
Examples of the importance of well-designed trials can be derived from the 
experience in colorectal cancer, where the use of bevacizumab in the adjuvant 
setting did not translate into improved outcome, and the simultaneous administration 
of both bevacizumab and cetuximab seems to even be detrimental.13  
Fifthly, do we know the best timing of bevacizumab? A source of concern is the 
rebound edema after discontinuation of bevacizumab. Because of this, salvage 
therapy after failure of bevacizumab has been particularly challenging, no drug or 
regimen either alone or in combination with bevacizumab has demonstrated 
activity.14 Should other treatments therefore be applied prior to initiating bevacizumab 
while withholding bevacizumab as long as possible? This will also impact the design 
of future trials in recurrent glioblastoma.  
Sixth, what is the significance of the gliomatosis cerebri like pattern of recurrence 
that has been observed in some of the bevacizumab and other VEGF signaling 
pathway interfering agents. Recent experience suggests induction of a more 
aggressive and diffusely invasive tumor phenotype as a mechanism of escape to 
anti-VEGF therapy.6,14 
Lastly, the accelerated approval of bevacizumab is likely to influence future drug 
development. It encourages cheap(er) drug development strategies based on phase 
II protocols, pre-registration wide-spread clinical use rather than conclusive phase III 
trials.  
 
There is no one generally agreed standard of care in recurrent glioblastoma, but an 
array of treatment options largely based on level III evidence. Ideally patients are 
enrolled into clinical trials. The numerous ongoing uncontrolled bevacizumab 
combination trials are unlikely to answer the most burning questions.From the 
patient’s perspective any clinical improvement leading to improved quality of life and 
with the least toxicity is of benefit. Such an effect is observed with bevacizumab in 
particular in patients with symptomatic peritumoral edema causing deficits and 
requiring steroids. But we lack properly designed trials how to best and most 
economically use the agent. The widespread use of bevacizumab even prior to the 
registration impedes on the possibility to conduct the appropriate trials that would 
answer these questions. Instead of conducting yet another uncontrolled study, 
attempts should be made to develop well-designed protocols that give answers to 
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